New drug combo aims to fight melanoma when standard therapy fails

NCT ID NCT04996823

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 2 study tests whether combining two drugs—axitinib (a targeted therapy) and ipilimumab (an immunotherapy)—can shrink tumors in people with advanced melanoma that has stopped responding to standard treatment. The trial plans to enroll 25 participants. Researchers will measure how many patients see their tumors shrink or disappear, and how long they live without the disease getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axitinib (Inlyta) and ipilimumab (Yervoy)
What this could lead to: If successful, this combination could offer a new treatment option for advanced melanoma patients who no longer respond to standard immunotherapy.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not expected to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.